Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

Bibliography

• Bradley WG. Overview of motor neuron disease: classification and nomenclature. Clin Neurosci 1995-1996;3:323-6
   PubMedGoogle Scholar
• Renton AE, Majounie E, Waite A, A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-68
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-56
   PubMed Web of Science ®Google Scholar
• Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009;4:3
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Lowe S. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. Pharmacoeconomics 2002;20:367-87
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Van Kammen M, Levey AI, Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
   PubMed Web of Science ®Google Scholar
• Guo H, Lai L, Butchbach ME, Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 2003;12:2519-32
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Clinical Trial Ceftriaxone in Subjects with ALS, July 2006. Available from: http://clinicaltrials.gov/ct2/results?term=NCT+00349622 [Last accessed 16 October 2011]
   Google Scholar
• Van Den Bosch L, Vandenberghe W, Klaassen H, Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 2000;180:29-34
   PubMed Web of Science ®Google Scholar
• Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999;46:806-15
   PubMed Web of Science ®Google Scholar
• Blin O, Azulay JP, Desnuelle C, A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 1996;19:189-92
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Bruijn L, Conwit R, Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20-7
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Shefner J, Chappell AS, A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:266-71
   PubMed Web of Science ®Google Scholar
• Clinical trials. Talampanel for Amyotrophic Lateral Sclerosis (ALS), September 2008. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00696332 [Last accessed 16 October 2011]
   Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 2005;22:2376-80
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Pinto S, Costa J, A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:456-60
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore D, Young LA, Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383-8
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH II, Gelinas DF, Western ALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-8
   PubMed Web of Science ®Google Scholar
• Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003;108:1-8
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Northeast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-64
   PubMed Web of Science ®Google Scholar
• Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996;381:571-9
   PubMed Web of Science ®Google Scholar
• Dierick I, Irobi J, Janssens S, Genetic variant in the HSPB1 promoter region impairs the HSP27 stress response. Hum Mutat 2007;28:830
   PubMed Web of Science ®Google Scholar
• Keizman D, Rogowski O, Berliner S, Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009;119:383-9
   PubMed Web of Science ®Google Scholar
• Batulan Z, Taylor DM, Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol Dis 2006;24:213-25
   PubMed Web of Science ®Google Scholar
• Vigh L, Literati PN, Horvath I, Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med 1997;3:1150-4
   PubMed Web of Science ®Google Scholar
• Hargitai J, Lewis H, Boros I, Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 2003;307:689-95
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JR, Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Phase II/III randomized, placebo-controlled trial of arimoclomol in SOD1 positive familial amyotrophic lateral sclerosis, January 2009. Available from: http://clinicaltrials.gov/ct2/results?term=NCT+00706147 [Last accessed 16 October 2011]
   Google Scholar
• Wright PD, Huang M, Weiss A, Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. Neurosci Lett 2010;482:188-92
   PubMed Web of Science ®Google Scholar
• Lange D. Pyrimethamine as therapy for SOD1 associated FALS: early findings. In 19th International Symposium on ALS/MND, Birmingham, UK, November 3-5, 2008. Amyotroph Lateral Scler 2008;9(Suppl 1):46
   Google Scholar
• Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2007;104:2495-500
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Fujiwara N, Ido A, Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2010;69:1044-56
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010;113:1188-99
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-8
   PubMed Web of Science ®Google Scholar
• Smith RA, Miller TM, Yamanaka K, Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116:2290-6
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Safety, Tolerability, and Activity Study of ISIS SOD1Rx to treat familial amyotrophic lateral sclerosis (ALS) caused by SOD1 gene mutations, January 2010. Available from: http://clinicaltrials.gov/ct2/results?term=NCT+01041222 [Last accessed 16 October 2011]
   Google Scholar
• Pasquali L, Longone P, Isidoro C, Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve 2009;40:173-94
   PubMed Web of Science ®Google Scholar
• Kabuta T, Suzuki Y, Wada K. Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J Biol Chem 2006;281:30524-33
   PubMed Web of Science ®Google Scholar
• Fornai F, Longone P, Cafaro L, Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-7
   PubMed Web of Science ®Google Scholar
• Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439-48
   PubMed Web of Science ®Google Scholar
• Sarkar S, Rubinsztein DC. Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst 2008;4:895-901
   PubMed Web of Science ®Google Scholar
• Aggarwal SP, Zinman L, Simpson E, Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481-8
   PubMed Web of Science ®Google Scholar
• Chio A, Borghero G, Calvo A, Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial; LITALS Study Group. Neurology 2010;75:619-25
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH, Forshew DA, WALS Study Group. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 2011;77:973-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu J, Pan H, Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci USA 2007;104:19023-8
   PubMed Web of Science ®Google Scholar
• Williams A, Sarkar S, Cuddon P, Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol 2008;4:295-05
   PubMed Web of Science ®Google Scholar
• Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457:981-9
   PubMed Web of Science ®Google Scholar
• Pawlyk AC, Cassel JA, Reitz AB. Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis. Curr Pharm Des 2010;16:2053-73
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Gelinas DF, Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62:1845-7
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-53
   PubMed Web of Science ®Google Scholar
• Waldmeier PC, Boulton AA, Cools AR, Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 2000;60:197-14
   PubMedGoogle Scholar
• Groeneveld GJ, van Muiswinkel FL, de Leeuw van Weenen J, CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:220-5
   PubMed Web of Science ®Google Scholar
• Miller R, Bradley W, Cudkowicz M, TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-84
   PubMed Web of Science ®Google Scholar
• Mioduszewska B, Jaworski J, Kaczmarek L. Inducible cAMP early repressor (ICER) in the nervous system- a transcriptional regulator of neuronal plasticity and programmed cell death. J Neurochem 2003;87:1313-20
   PubMed Web of Science ®Google Scholar
• Meininger V, Asselain B, Guillet P, Pentoxifylline European Group. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 2006;66:88-92
   PubMed Web of Science ®Google Scholar
• Castro RE, Sola S, Ramalho RM, The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther 2004;311:845-52
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Efficacy and tolerability of tauroursodeoxycholic acid in amyotrophic lateral sclerosis, June 2008. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00877604 [Last accessed 16 October 2011]
   Google Scholar
• Clinical Trials. Cistanche total glycosides for amyotrophic lateral sclerosis: a randomized control trial (RCT) study assessing clinical response, January 2008. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00753571 [Last accessed 16 October 2011]
   Google Scholar
• Sasaki S, Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996;47:535-40
   PubMed Web of Science ®Google Scholar
• Atsumi T, Miyatake T. Morphometry of the degenerative process in the hypoglossal nerves in amyotrophic lateral sclerosis. Acta Neuropathol 1987;73:25-31
   PubMed Web of Science ®Google Scholar
• Dupuis L, di Scala F, Rene F, Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J 2003;17:2091-3
   PubMed Web of Science ®Google Scholar
• Israelson A, Arbel N, Da Cruz S, Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 2010;67:575-87
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, NEALS Consortium. A clinical trial of creatine in ALS. Neurology 2004;63:1656-61
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS), March 2011. Available from: http://clinicaltrials.gov/ct2/results?term=NCT01257581 [Last accessed 16 October 2011]
   Google Scholar
• Bordet T, Buisson B, Michaud M, Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709-20
   PubMed Web of Science ®Google Scholar
• Trophos announces results of phase 3 study of olesoxime in Amyotrophic Lateral Sclerosis. Trophos: Press Release, December 2011. Available from: http://www.trophos.com/news/pr20111213.htm [Last accessed 5 January 2012]
   Google Scholar
• Danzeisen R, Schwalenstoecker B, Gillardon F, Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006;316:189-99
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Phase 3 Study of Dexpramipexole in ALS, March 2011. Available from: http://clinicaltrials.gov/ct2/results?term=NCT01281189 [Last accessed 16 October 2011]
   Google Scholar
• Tan DX, Reiter RJ, Manchester LC, Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002;2:181-97
   PubMedGoogle Scholar
• Wang X, Figueroa BE, Stavrovskaya IG, Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke 2009;40:1877-85
   PubMed Web of Science ®Google Scholar
• Weishaupt JH, Bartels C, Polking E, Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006;41:313-23
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18
   PubMed Web of Science ®Google Scholar
• Kwiecinski H, Janik P, Jamrozik Z, Opuchlik A. The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials. Neurol Neurochir Pol 2001;35(1 Suppl):101-6
   PubMedGoogle Scholar
• Andreassen OA, Dedeoglu A, Klivenyi P, N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000;11:2491-3
   PubMed Web of Science ®Google Scholar
• Henderson JT, Javaheri M, Kopko S, Roder JC. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J Neurosci 1996;16:7574-82
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Weverling GJ, Bossuyt PM, Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-64
   PubMed Web of Science ®Google Scholar
• Sohmiya M, Tanaka M, Suzuki Y, An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005;228:49-53
   PubMed Web of Science ®Google Scholar
• Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002;36:455-60
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66:235-44
   PubMed Web of Science ®Google Scholar
• Crow JP, Calingasan NY, Chen J, Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 2005;58:258-65
   PubMed Web of Science ®Google Scholar
• Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 2006;7:70-80
   PubMed Web of Science ®Google Scholar
• Siciliano G, Carlesi C, Pasquali L, Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets 2010;9:305-13
   PubMed Web of Science ®Google Scholar
• Vyth A, Timmer JG, Bossuyt PM, Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci 1996;139(Suppl):99-103
   PubMed Web of Science ®Google Scholar
• Almer G, Guegan C, Teismann P, Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176-85
   PubMed Web of Science ®Google Scholar
• Maihofner C, Probst-Cousin S, Bergmann M, Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003;18:1527-34
   PubMed Web of Science ®Google Scholar
• Kelley KA, Ho L, Winger D, Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999;155:995-04
   PubMed Web of Science ®Google Scholar
• Iadecola C, Niwa K, Nogawa S, Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 2001;98:1294-9
   PubMed Web of Science ®Google Scholar
• Drachman DB, Frank K, Dykes-Hoberg M, Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52:771-8
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60:22-31
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Safety and tolerability of anakinra in combination with riluzol in amyotrophic lateral sclerosis, February 2011. Available from: http://clinicaltrials.gov/ct2/results?term=NCT01277315 [Last accessed 16 October 2011]
   Google Scholar
• Holmøy T. T cells in amyotrophic lateral sclerosis. Eur J Neurol 2008;15:360-6
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Zhao W, CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA 2008;105:15558-63
   PubMed Web of Science ®Google Scholar
• Habisch HJ, Schwalenstocker B, Danzeisen R, Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS. Exp Neurol 2007;206:288-95
   PubMed Web of Science ®Google Scholar
• Gordon PH, Doorish C, Montes J, Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 2006;66:1117-19
   PubMed Web of Science ®Google Scholar
• Meininger V, Drory VE, Leigh PN, Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009;10:378-83
   PubMed Web of Science ®Google Scholar
• Papadimitriou D, Le Verche V, Jacquier A, Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis 2010;37:493-502
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067-70
   PubMed Web of Science ®Google Scholar
• Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-78
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11
   PubMed Web of Science ®Google Scholar
• Kiaei M, Petri S, Kipiani K, Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:2467-73
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Phase II study using thalidomide for the treatment of ALS, February 2005. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00140452 [Last accessed 16 October 2011]
   Google Scholar
• A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 1999;52(7):1427-33
   PubMed Web of Science ®Google Scholar
• Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004(3):CD004302
   Google Scholar
• Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007(4):CD002064
   Google Scholar
• Mizisin AP, DiStefano PS, Liu X, Decreased accumulation of endogenous brain-derived neurotrophic factor against constricting sciatic nerve ligatures in streptozotocin-diabetic and galactose-fed rats. Neurosci Lett 1999;263:149-52
   PubMed Web of Science ®Google Scholar
• Seeburger JL, Springer JE. Experimental rationale for the therapeutic use of neurotrophins in amyotrophic lateral sclerosis. Exp Neurol 1993;124:64-72
   PubMed Web of Science ®Google Scholar
• Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:22-6
   PubMed Web of Science ®Google Scholar
• Beck M, Flachenecker P, Magnus T, Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:100-3
   PubMed Web of Science ®Google Scholar
• Vincent AM, Mobley BC, Hiller A, Feldman EL. IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis 2004;16:407-16
   PubMed Web of Science ®Google Scholar
• Anlar B, Sullivan KA, Feldman EL. Insulin-like growth factor-I and central nervous system development. Horm Metab Res 1999;31:120-5
   PubMed Web of Science ®Google Scholar
• Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998;50:772-6
   PubMed Web of Science ®Google Scholar
• Hosback S, Hardiman O, Nolan CM, Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res 2007;17:472-9
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-30
   PubMed Web of Science ®Google Scholar
• Borasio GD, Robberecht W, Leigh PN, A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-6
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Windbank AJ, Mandrekar JN, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71:1770-5
   PubMed Web of Science ®Google Scholar
• Oosthuyse B, Moons L, Storkebaum E, Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8
   PubMed Web of Science ®Google Scholar
• Zheng C, Nennesmo I, Fadeel B, Henter JI. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2004;56:564-7
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Dewerchin M, Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92
   PubMed Web of Science ®Google Scholar
• Clinical Trial. A Safety and tolerability study of intracerebroventricular administration of sNN0029 to patients with amyotrophic lateral sclerosis, December 2008. Available from: http://clinicaltrials.gov/ct2/results?term=NCT+00800501 [Last accessed 16 October 2011]
   Google Scholar
• Pitzer C, Kruger C, Plaas C, Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008;131:3335-47
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, La Bella V, STEMALS Study Group. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011;43:189-95
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Fu Y, Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:430-1
   PubMed Web of Science ®Google Scholar
• Nefussy B, Artamonov I, Deutsch V, Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: a pilot study. Amyotroph Lateral Scler 2010;11:187-93
   PubMed Web of Science ®Google Scholar
• Fournier J, Steinberg R, Gauthier T, Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 1993;55:629-41
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Douillet P, Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:99-106
   PubMed Web of Science ®Google Scholar
• Meininger V, Bensimon G, Bradley WR, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler OtherMotor Neuron Disord 2004;5:107-17
   PubMed Web of Science ®Google Scholar
• Gao J, Coggeshall RE, Chung JM, Functional motoneurons develop from human neural stem cell transplants in adult rats. Neuroreport 2007;18:565-9
   PubMed Web of Science ®Google Scholar
• Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23:249-56
   PubMed Web of Science ®Google Scholar
• Xu L, Ryugo DK, Pongstaporn T, Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009;514:297-309
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Nardini M, Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum Mol Genet 2010;19:3782-96
   PubMed Web of Science ®Google Scholar
• de Filippis L. Neural stem cell-mediated therapy for rare brain diseases: perspectives in the near future for LSDs and MNDs. Histol Histopathol 2011;26:1093-1109
   PubMed Web of Science ®Google Scholar
• Gamez J, Carmona F, Raguer N, Cellular transplants in amyotrophic lateral sclerosis patients: an observational study. Cytotherapy 2010;12:669-77
   PubMed Web of Science ®Google Scholar
• Blanquer M, Perez Espejo MA, Iniesta F, Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial. Methods Find Exp Clin Pharmacol 2010;32:31-7
   PubMedGoogle Scholar
• Deda H, Inci MC, Kurekci AE, Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18-25
   PubMed Web of Science ®Google Scholar
• Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009;11:26-34
   PubMed Web of Science ®Google Scholar
• Clinical Trial. A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS), March 2010. Available from: http://clinicaltrials.gov/ct2/results?term=NCT+01089010 [Last accessed 16 October 2011]
   Google Scholar
• Shefner J. Rationale and design for Phase IIa Study evaluating CK-2017357, a novel activator of fast skeletal muscle, in patients with ALS. 21st International Symposium on ALS/MND; 11 – 13 December 2010; Orlando, FL, USA
   Google Scholar
• Clinical Trials. A Safety, tolerability, pharmacokinetic and pharmacodynamic study of ACE-031 in healthy postmenopausal women, August 2009. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00952887 [Last accessed 16 October 2011]
   Google Scholar
• Cadena SM, Tomkinson KN, Monnell TE, Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010;109:635-42
   PubMed Web of Science ®Google Scholar
• Borgstein NG, Barger R, Yang Y, A phase I multiple ascending dose study to assess the pharmacodynamic effects of ACE-031, an inhibitor of negative muscle regulators in healthy volunteers Poster P3.18. 15th International Congress of the World Muscle Society; 12 – 16 October 2010; Kunamoto, Japan
   Google Scholar
• Jokic N, Gonzalez de Aguilar JL, Pradat PF, Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005;57:553-6
   PubMed Web of Science ®Google Scholar
• Jokic N, Gonzalez de Aguilar JL, Dimou L, The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006;7:1162-7
   PubMed Web of Science ®Google Scholar
• Liu BP, Cafferty WB, Budel SO, Strittmatter SM. Extracellular regulators of axonal growth in the adult central nervous system. Philos Trans R Soc Lond B Biol Sci 2006;361:1593-10
   PubMed Web of Science ®Google Scholar
• Clinical Trial. First time in human study of GSK1223249 in amyotrophic lateral sclerosis, May 2009. Available from: http://clinicaltrials.gov/ct2/results?term=NCT+00875446 [Last accessed 16 October 2011]
   Google Scholar
• Rutkove S. Electrical impedance myography as a biomarker for ALS. Lancet Neurol 2009;8:226; author reply 227
   PubMed Web of Science ®Google Scholar
• Yarn JC. Disappointments in medicine: lack of effective treatment for neurological disorders like ALS. Can Fam Physician 2011;57:333
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-31
   PubMed Web of Science ®Google Scholar
• Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55:526-8
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002;249:609-15
   PubMed Web of Science ®Google Scholar
• Mitchell JD, O'brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler 2006;7:67-71
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, An outcome study of riluzole in amyotrophic lateral sclerosis- a population-based study in Ireland, 1996-2000. J Neurol 2003;250:473-9
   PubMed Web of Science ®Google Scholar
• Phase 2 study of talampanel for the treatment of amyotrophic lateral sclerosis (ALS). Monthly Prescribing Reference. News Drugs in the Pipeline, May 2010. Available from: http://www.empr.com/phase-2-study-of-talampanel-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/article/170351/ [Last accessed 5 January 2012]
   Google Scholar
• Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate (dexpramipexole). Biogen Idec. Press Release Details, August 2010. Available from: http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1461011 [Last accessed 16 October 2011]
   Google Scholar
• Amyotrophic Lateral Sclerosis (ALS) AEOL10150. Center Watch. New Medical Therapies, December 2007. Available from: http://www.centerwatch.com/clinical-trials/results/new-therapies/nmt-details.aspx?CatID=160 [Last accessed 16 October 2011]
   Google Scholar
• Stommel EW, Cohen JA, Fadul CE, Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler 2009;10:393-404
   PubMed Web of Science ®Google Scholar
• Meyer T, Maier A, Borisow N, Thalidomide causes sinus bradycardia in ALS. J Neurol 2008;255:587-91
   PubMed Web of Science ®Google Scholar